{"id":4620,"date":"2019-04-02T17:52:02","date_gmt":"2019-04-02T12:22:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4620"},"modified":"2021-07-24T12:57:16","modified_gmt":"2021-07-24T07:27:16","slug":"notizia-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f837f1676f0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f837f1676f0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\/#Selumetinib_gets_the_US_Breakthrough_Therapy_Designation\" >Selumetinib gets the U.S. Breakthrough Therapy Designation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\/#FDA_approves_the_first_drug_for_a_type_of_inflammatory_arthritis\" >FDA approves the first drug for a type of inflammatory arthritis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\/#Apexigen_BMS_reports_positive_results_for_I-O_therapy_to_treat_Pancreatic_Cancer\" >Apexigen, BMS reports positive results for I-O therapy\nto treat Pancreatic Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\/#Green_signal_to_the_Merck_KGaAs_drug_Mavenclad\" >Green signal to the Merck KGaA\u2019s drug\nMavenclad<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Selumetinib_gets_the_US_Breakthrough_Therapy_Designation\"><\/span><strong>Selumetinib gets the U.S. Breakthrough Therapy Designation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Selumetinib- <\/strong>an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and\/or progressive, inoperable <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neurofibromatoses-pipeline-insight\">neurofibromatosis <\/a>type 1 (NF1)<\/strong>, <strong>plexiform neurofibromas<\/strong> (PN)- a rare genetic condition, has been granted the <strong>Breakthrough Therapy Designation<\/strong> (BTD) from the U.S. <strong>FDA<\/strong>. Selumetinib is a <strong>MEK- \u00bd inhibitor<\/strong> jointly developed by <strong>AstraZeneca<\/strong> and <strong>Merck<\/strong> has shown promising improvements and proven to be of clinical significance. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approves_the_first_drug_for_a_type_of_inflammatory_arthritis\"><\/span><strong>FDA approves the first drug for a type of inflammatory arthritis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">In the very first<strong>, the U.S. <a href=\"https:\/\/www.fda.gov\/\">FDA <\/a><\/strong>has approved <strong>Cimzia<\/strong> (<strong>certolizumab pegol<\/strong>) injection for treating a certain type of inflammatory arthritis called <strong>non-radiographic axial spondyloarthritis (nr-axSpA),<\/strong> with objective signs of inflammation<strong>. <\/strong>The approval will benefit the patients suffering from <strong>nr-axSpA<\/strong> fulfilling their unmet medical needs. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Apexigen_BMS_reports_positive_results_for_I-O_therapy_to_treat_Pancreatic_Cancer\"><\/span><strong>Apexigen, BMS reports positive results for I-O therapy\nto treat Pancreatic Cancer <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Apexigen<\/strong> lead <strong>Immuno-oncology drug<\/strong> candidate, <strong>APX005M, <\/strong>further rolled it out into clinical trials after its splendid performance at the <g class=\"gr_ gr_5 gr-alert gr_gramm gr_inline_cards gr_run_anim Grammar only-ins replaceWithoutSep\" id=\"5\" data-gr-id=\"5\">annual<\/g> <strong>American Association for Cancer Research<\/strong> (AACR) meeting in Atlanta. The combination of APX005M-a <strong>CD40-activating<\/strong> <strong>antibody <\/strong>and<strong> PD-1 inhibitor Opdivo<\/strong> developed by<strong> Bristol-Myers Squibb\u2019s <\/strong>along with chemotherapy are designed in a specialized way to target and fight cancer in patients with advanced <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\">pancreatic cancer<\/a><\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Green_signal_to_the_Merck_KGaAs_drug_Mavenclad\"><\/span><strong>Green signal to the Merck<\/strong> <strong>KGaA\u2019s drug\n<\/strong><strong>Mavenclad<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The U.S. <strong>FDA <\/strong>has given its nod for the use of<strong> Mavenclad (cladribine)- <\/strong>a new oral treatment, to treat relapsing forms of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-progressive-multiple-sclerosis-ppms-market\">Multiple Sclerosis<\/a><\/strong> including <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-multiple-sclerosis-rms-market\">relapsing-remitting disease <\/a><\/strong>(RRMS) and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/secondary-progressive-multiple-sclerosis-spms-market\">active secondary progressive disease<\/a><\/strong> (SPMS). Although because of the associated risks it has been approved only for those patients who fail to respond to other alternative drugs for MS. But <strong>Mavenclad <\/strong>isn\u2019t the only candidate standing. For the same indication <strong>Novartis<\/strong>\u2019 <strong>Mayzent<\/strong>, also got approved not more than a week ago. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and\/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has been granted the Breakthrough Therapy Designation (BTD) from the U.S. FDA. Selumetinib is a MEK- [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,137,139,3066,704,3056,3053,3061,395,2537,1497,3060,1848,449,3069,3059,3055],"industry":[17225],"therapeutic_areas":[17229,17245,17228,17234],"class_list":["post-4620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-cancer","tag-cancer-chemotherapy","tag-cimzia","tag-fda","tag-mavenclad","tag-mayzent","tag-mek--inhibitor","tag-merck","tag-merck-kgaa","tag-multiple-sclerosis","tag-neurofibromatosis","tag-novartis-venture-fund","tag-pancreatic-cancer","tag-pd-1-inhibitor","tag-plexiform-neurofibromas","tag-selumetinib","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 02\/04\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The U.S. FDA has given its nod for the use of Mavenclad (cladribine)- a new oral treatment, to treat relapsing forms of Multiple Sclerosis including...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 02\/04\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The U.S. FDA has given its nod for the use of Mavenclad (cladribine)- a new oral treatment, to treat relapsing forms of Multiple Sclerosis including...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-02T12:22:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202.png\" \/>\n\t<meta property=\"og:image:width\" content=\"672\" \/>\n\t<meta property=\"og:image:height\" content=\"535\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 02\/04\/2019 - DelveInsight Business Research","description":"The U.S. FDA has given its nod for the use of Mavenclad (cladribine)- a new oral treatment, to treat relapsing forms of Multiple Sclerosis including...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis","og_locale":"en_US","og_type":"article","og_title":"Notizia 02\/04\/2019 - DelveInsight Business Research","og_description":"The U.S. FDA has given its nod for the use of Mavenclad (cladribine)- a new oral treatment, to treat relapsing forms of Multiple Sclerosis including...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-02T12:22:02+00:00","article_modified_time":"2021-07-24T07:27:16+00:00","og_image":[{"width":672,"height":535,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis","url":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis","name":"Notizia 02\/04\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202.png","datePublished":"2019-04-02T12:22:02+00:00","dateModified":"2021-07-24T07:27:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The U.S. FDA has given its nod for the use of Mavenclad (cladribine)- a new oral treatment, to treat relapsing forms of Multiple Sclerosis including...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-multiple-sclerosis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202.png","width":672,"height":535,"caption":"Multiple Sclerosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021810\/Capture202-300x239.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cancer chemotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cimzia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mavenclad<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mayzent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MEK- \u00bd inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck KGaA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">neurofibromatosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis Venture Fund<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PD-1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">plexiform neurofibromas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Selumetinib<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">cancer chemotherapy<\/span>","<span class=\"advgb-post-tax-term\">Cimzia<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Mavenclad<\/span>","<span class=\"advgb-post-tax-term\">Mayzent<\/span>","<span class=\"advgb-post-tax-term\">MEK- \u00bd inhibitor<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Merck KGaA<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">neurofibromatosis<\/span>","<span class=\"advgb-post-tax-term\">Novartis Venture Fund<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">PD-1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">plexiform neurofibromas<\/span>","<span class=\"advgb-post-tax-term\">Selumetinib<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 2, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 2, 2019 5:52 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4620"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4620\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4621"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4620"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4620"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}